241 related articles for article (PubMed ID: 29346605)
1. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation.
DeLoughery EP; Prasad V
Ann Oncol; 2018 Mar; 29(3):527-529. PubMed ID: 29346605
[No Abstract] [Full Text] [Related]
2. They are from the government and they really are here to help you.
Woosley RL
J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
[No Abstract] [Full Text] [Related]
3. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
4. Adaptive enrichment designs for confirmatory trials.
Lai TL; Lavori PW; Tsang KW
Stat Med; 2019 Feb; 38(4):613-624. PubMed ID: 30277591
[TBL] [Abstract][Full Text] [Related]
5. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
Liu ITT; Kesselheim AS; Cliff ERS
JAMA; 2024 May; 331(17):1471-1479. PubMed ID: 38583175
[TBL] [Abstract][Full Text] [Related]
6. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ
Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815
[TBL] [Abstract][Full Text] [Related]
7. Challenges and opportunities in bringing new medications to market for pediatric patients.
Upadhyaya HP; Gault L; Allen AJ
J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1056-1059. PubMed ID: 19855220
[No Abstract] [Full Text] [Related]
8. Oncology drug development: United States Food and Drug Administration perspective.
Hirschfeld S; Pazdur R
Crit Rev Oncol Hematol; 2002 May; 42(2):137-43. PubMed ID: 12007971
[TBL] [Abstract][Full Text] [Related]
9. Moment of reckoning.
Wadman M
Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
[No Abstract] [Full Text] [Related]
10. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
11. Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.
Farrell AT; Goldberg KB; Pazdur R
Blood; 2017 Sep; 130(11):1285-1289. PubMed ID: 28774876
[No Abstract] [Full Text] [Related]
12. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials.
Tibau A; Molto C; Borrell M; Del Paggio JC; Barnadas A; Booth CM; Amir E
JAMA Oncol; 2018 Nov; 4(11):1610-1611. PubMed ID: 30267037
[TBL] [Abstract][Full Text] [Related]
13. FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer.
Gyawali B; Kesselheim AS
Nat Rev Clin Oncol; 2021 Jul; 18(7):397-398. PubMed ID: 33767454
[No Abstract] [Full Text] [Related]
14. The needs of the few.
Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
[No Abstract] [Full Text] [Related]
15. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
Leighton JK; Saber H; Reaman G; Pazdur R
Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
[No Abstract] [Full Text] [Related]
16. Recasting cancer trials.
Nat Biotechnol; 2012 Jul; 30(7):567. PubMed ID: 22781659
[No Abstract] [Full Text] [Related]
17. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
[TBL] [Abstract][Full Text] [Related]
18. Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program.
Epstein MS; Shah ED; Deepak P; Kushnir VM
Am J Gastroenterol; 2019 Jul; 114(7):1017-1019. PubMed ID: 31033521
[No Abstract] [Full Text] [Related]
19. The role of the fDA in cancer clinical trials.
Hirschfeld S
Cancer Treat Res; 2007; 132():51-109. PubMed ID: 17305017
[No Abstract] [Full Text] [Related]
20. Experimental drugs on trial.
Benderly BL
Sci Am; 2007 Oct; 297(4):92-9. PubMed ID: 17926760
[No Abstract] [Full Text] [Related]
[Next] [New Search]
